Myelodysplastic syndromes in a pediatric patient with Cri du Chat syndrome with a ring chromosome 5

Int J Hematol. 2020 Nov;112(5):728-733. doi: 10.1007/s12185-020-02909-7. Epub 2020 Jun 9.

Abstract

Few hematological complications have previously been reported in association with Cri du Chat syndrome (CdCS). A case of myelodysplastic syndromes (MDS) in a pediatric patient with CdCS is herein presented. A 17-year-old female with CdCS caused by ring chromosome 5 was admitted to the hospital for investigation of a 1-month history of anemia. Based on the morphological findings of bone marrow, the patient was diagnosed with refractory cytopenia with multilineage dysplasia. The risk group was classified as intermediate-1 in the International Prognostic Scoring System (IPSS), and low in the revised IPSS. Assessment by microarray comparative genomic hybridization (CGH) identified the breakpoints of ring chromosome 5 as 46,XX,r(5)(p14.3q35.3). This revealed that the 5q terminal deletion did not include the common deleted region of MDS with del(5q). Treatment with azacitidine was initiated to control disease progression and improve quality of life. At baseline, the patient had a mean transfusion requirement of 3 units/month, which decreased to 2 units/month after six cycles of azacitidine and to 1 unit/month after 10 cycles of azacitidine. Cytopenia observed in the presented case seemed irrelevant to ring chromosome 5 which is the causative cytogenetic abnormality of CdCS, and further analyses may be needed to clarify the pathogenesis.

Keywords: Heterozygous missense mutation; Microarray comparative genomic hybridization; Neurofibromatosis type 1; Pediatric hematology; Ring chromosome 5.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Age Factors
  • Azacitidine / administration & dosage*
  • Chromosome Deletion*
  • Chromosomes, Human, Pair 5 / genetics*
  • Cri-du-Chat Syndrome / etiology
  • Cri-du-Chat Syndrome / genetics*
  • Cytogenetic Analysis / methods
  • Female
  • Humans
  • Myelodysplastic Syndromes / blood
  • Myelodysplastic Syndromes / drug therapy*
  • Myelodysplastic Syndromes / etiology*
  • Myelodysplastic Syndromes / genetics*
  • Quality of Life
  • Ring Chromosomes*
  • Treatment Outcome

Substances

  • Azacitidine